Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) Non Operating Income (2021 - 2025)

Valion Bio has reported Non Operating Income over the past 4 years, most recently at -$113000.0 for Q3 2025.

  • For Q3 2025, Non Operating Income changed N/A year-over-year to -$113000.0; the TTM value through Sep 2025 reached -$100000.0, down 75.44%, while the annual FY2024 figure was $6000.0, 500.0% up from the prior year.
  • Non Operating Income for Q3 2025 was -$113000.0 at Valion Bio, down from $3000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $6000.0 in Q4 2024 and troughed at -$1.4 million in Q4 2021.
  • A 4-year average of -$274272.7 and a median of -$39000.0 in 2021 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: soared 100.21% in 2022 and later skyrocketed 105.0% in 2025.
  • Year by year, Non Operating Income stood at -$1.4 million in 2021, then skyrocketed by 100.21% to $3000.0 in 2022, then surged by 100.0% to $6000.0 in 2024, then plummeted by 1983.33% to -$113000.0 in 2025.
  • Business Quant data shows Non Operating Income for TIVC at -$113000.0 in Q3 2025, $3000.0 in Q2 2025, and $4000.0 in Q1 2025.